May 2026 in “Journal of Clinical Medicine” This meta-analysis found a significantly higher prevalence of depressive symptoms in women with PCOS compared to a control group, with 42.11% versus 13.62% according to the BDI assessment, highlighting the need for psychiatric evaluation and support for women with this syndrome.
November 2025 in “Anxiety Stress & Coping” This study found that generalized anxiety disorder symptoms predicted higher emotional distress and hair cortisol concentration, with dominance unexpectedly increasing the impact of anxiety on hair cortisol.
January 2026 in “Journal of Pharmacy & Bioresources” This study found that 44.3% of patients with benign prostatic hyperplasia experienced high anxiety levels, which were significantly associated with residual symptoms and demographic factors.
June 2026 in “Drugs & Therapy Perspectives” This study reports that patients with severe alopecia areata who experienced sustained scalp regrowth while receiving continuous baricitinib treatment showed improvements in health-related quality of life and reductions in anxiety and depression symptoms.
November 2023 in “JEADV Clinical Practice” In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.